Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive Dysfunction
Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Chip® (HoaC) single- and multi-organ systems platform, is pleased to announce the publication of a new peer-reviewed study, developed in collaboration with Bayer Consumer Health. The study introduces the first human-relevant microphysiological system (MPS) capable of modeling central nervous system (CNS) stress responses and evaluating potential therapeutic compounds. The full paper, “Developing a Functional Non-Animal CNS Stress Model Utilizing Long-Term Potentiation with Human iPSC-Cortical Neurons to Evaluate Therapeutics,” is now available in Biomedicine & Pharmacotherapy.
Hesperos Demonstrates First Digital Twin of Human Disease Using Organ-on-a-Chip Platform
Hesperos, Inc., a leader in recapitulating human physiology and diseases for drug development using its Human-on-a-Chip® single- and multi-organ systems, today announced the publication of a groundbreaking study in Advanced Science. The study introduces the first true digital twin capability using an organ-on-a-chip platform, also known as a microphysiological system (MPS). This marks a significant leap forward in the development of human-relevant, non-animal testing systems for disease modeling, drug screening, and regulatory decision-making.
Hesperos and UCF Researchers Develop Human-on-a-Chip® Platform to Address Opioid Crisis
Hesperos, Inc., in collaboration with researchers from the University of Central Florida (UCF), has developed a multi-organ, microphysiological acute opioid overdose and recovery (AOOR) model designed to help researchers address the persistent opioid crisis. Utilizing a human cell-based platform, the model can replicate overdose and successful recovery and permit researchers to study the effects of the recovery agent on each organ. In addition to reproducing efficacy, the model can also characterize off-target toxicity.
Hesperos and UCF Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation and Treatment Development for Peripheral Nervous System Diseases
Hesperos, a leader in recreating human biology with its’ Human-on-a-Chip® platform, has announced a breakthrough development of a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. Published in ACS Biomaterials, the work was done in collaboration with the University of Central Florida (UCF). This in vitro model enables the study and development of treatments for currently treatment deficient, rare diseases affecting the peripheral nervous system, such as Charcot-Marie-Tooth (CMT) disease, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Animal and simple in vitro models have had limited relevance for these human nervous system diseases.
Hesperos, Inc. Appoints Lawrence Florin as Chief Executive Officer to Lead Company Growth
Hesperos, Inc., a pioneer in recreating human biology for drug development with its Human-on-a-Chip® technology, is pleased to announce the appointment of Lawrence (Larry) Florin as Chief Executive Officer. Mr. Florin brings over two decades of leadership experience in the bio / clinical technology arenas, with a proven track record in clinical development, business growth, and strategic innovation.
Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial with its Human-on-a-Chip®
Hesperos, a leader in recreating human biology for drug discovery, is pleased to announce its Human-on-a-Chip® technology played a role in supporting a client’s Investigational New Drug submission with the Food & Drug Administration for a Phase II clinical trial of its investigational product DNTH103, highlighting the contribution of in vitro proof-of-concept data.
New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer’s Disease Progression, and Response to Therapeutics
Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their study, “A functional aged human iPSC-cortical neuron model recapitulates Alzheimer’s disease, senescence, and the response to therapeutics," has been published in the prestigious journal Alzheimer's & Dementia®: The Journal of the Alzheimer's Association. doi.org/10.1002/alz.14044
NIH Awards Hesperos Research Grant to Develop Animal-Free Botox Testing Platform
Hesperos, a leader in emulating human biology for drug discovery, was awarded a $2 million research grant by the National Center for Advancing Translational Sciences (NCATS) in collaboration with the U.S. Food and Drug Administration (FDA). The goal of the effort is to develop an advanced testing platform capable of assessing the potency of the Botulinum Toxin (BoT) without the need for animal testing.
New Study Describes First, Functional Human Model to Investigate Opiate Overdose and Recovery
A research team from the University of Central Florida and Hesperos, a pioneer in human-on-a-chip technology, has developed the first human model to study the effects of an opioid overdose and reversal with naloxone. The study, "Human IPSC-Derived PreBötC-like Neurons and Development of an Opiate Overdose and Recovery Model" (doi.org/10.1002/adbi.202300276) was published in Advanced Biology on September 7, 2023. The paper describes the development of human preBötC neurons from induced pluripotent cells (iPSCs) and the establishment of a human model that mimics opioid overdose with four opioids and the recovery of neuronal activity with naloxone treatment.
International Microphysiological Systems Society formally established at MPS World Summit, 2023
The International Microphysiological Systems Society (IMPSS) was officially established during the second MPS World Summit in Berlin, Germany on June 30, 2023. The conference brought together stakeholders from funding agencies, regulators, commercial developers, and end-users to discuss the latest developments and the future of human-based drug discovery tools. The attendance tripled from the previous year, indicating the growing interest and excitement in this field, with close to 1300 attendees and 96 sponsors, and the meeting next year is expected to continue this trend.
Hesperos Scientists Publish a New Study in Scientific Reports Titled: "Development of a Human Malaria-on-a-Chip Disease Model for Drug Efficacy and Off-Target Toxicity Evaluation"
It starts with a bite. You may not even notice until moments later when swatting away the mosquito and you begin to scratch at the resulting small welt on your skin. Aside from the annoyance of the itchy discomfort you would have no idea that at that moment one of the most insidious global infections had infiltrated your body. Over time you may present with incessant chills, an unrelenting fever, body aches, and nausea as the parasite proliferates. Maybe it’s a bad cold - or worse, the flu. When in reality, with each passing hour, a disease that has claimed up to 300 million lives in the last century is wreaking havoc on your body. In 2021 the World Health Organization reported 247 million cases of malaria - 619,000 of which resulted in loss of human life.
Hesperos, Inc. Appoints New Chief Executive Officer, Dr. James Kronauge
Hesperos Inc., leaders in Human-on-a-Chip®, in vitro systems, today announced the recent appointment of a new Chief Executive Officer (CEO), Dr. James Kronauge, effective April 1, 2022. Dr. Kronauge has over 30 years’ experience developing novel therapeutics and imaging biomarkers in both academia and industry.
